One-Shot gene therapy tested to halt Parkinson's progression
NCT ID NCT07011771
Summary
This early-stage trial is testing a new, one-time gene therapy called CAP-003 in adults with Parkinson's disease caused by a specific genetic change (GBA1 mutation). The main goals are to see if the treatment is safe and to look for early signs that it might help control the disease. About 31 participants will receive a single infusion and be closely monitored for two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GBA1 PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Booth Gardner Parkinson's Care Center - Evergreen Neuroscience Institute
Kirkland, Washington, 98034, United States
-
Inland Northwest Research
Spokane, Washington, 99202, United States
-
New York Presbyterian Hospital-Columbia University Medical Center
New York, New York, 10032, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.